Clinical Trial Update: Treg Therapy in Subclinical Inflammation in Kidney Transplantation [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating regulatory T cell therapy for subclinical inflammation in adult living donor kidney transplant recipients; the study is completed and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Treg Therapy (regulatory T cell therapy)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Kidney Transplant, Adult Living Donor Kidney Transplant Recipients | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-10-08